FLT3 and acute myeloid leukemia: The presence of FLT3 mutations in AML patients has traditionally been associated with an inferior prognosis, although recent advances, including modifying the impact of FLT3 inhibitors, increasing the use of minimal residual disease monitoring, and better prognoses with allogeneic stem cell transplantation, have improved the prognosis of this subgroup of AML patients which are currently classified in the intermediate prognosis group [1].